Lynda Polgreen is an Endocrinology/Metabolic physician affiliated with UCLA Medical Center. OpenAlex indexes 145 publications with 2,289 citations (h-index 26); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1201 W La Veta Ave
Orange, CA 928684203
Telephone
714-509-8634Provider last certified this registry record 3 Dec 2020.
Clinical trials
- Open-label Study of Anakinra in MPS III
Sponsor: Lynda E Polgreen
- Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- ACTIMMUNE in Intermediate Osteopetrosis
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BioMarin Pharmaceutical Inc.Program year20253 payments
- PFIZER INC.Program year20251 payment
- Eton Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Child & Adolescent Health
2023 - Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, <scp>II</scp>, and <scp>VI</scp>: Data from a 10‐year prospective study
Journal of Inherited Metabolic Disease
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Anthony Bohan, MD, JD
UCLA Medical Center
Ira Lesser, MD
UCLA Medical Center
Darryl Sue, MD
UCLA Medical Center
Andrew Gianoukakis, MD
UCLA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”